Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry J Copeland

Showing results (51-60 of 103) with videos related to

Pageof 11
Sort By:
Human Pathology|August 7, 2004
Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative imagesJeffrey D Seidman, Robert A Soslow, Russell Vang, et al.
Gynecologic Oncology|January 30, 2013
Neuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage diseaseGeorgia A McCann, Christina E Boutsicaris, Megan M Preston, et al.
Gynecologic Oncology|August 2, 2014
Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?Floor J Backes, Caroline C Billingsley, Douglas D Martin, et al.
Gynecologic Oncology|February 15, 2011
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancerDavid M O'Malley, Debra L Richardson, Patrick S Rheaume, et al.
Gynecologic Oncology|November 10, 2012
The impact of close surgical margins after radical hysterectomy for early-stage cervical cancerGeorgia A McCann, Susanne K Taege, Christina E Boutsicaris, et al.
Gynecologic Oncology|July 10, 2026
Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter?Paulina J Haight, Julia C Sakach, Laura M Chambers, et al.
Gynecologic Oncology|August 28, 2023
Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship periods following surgical management of endometrial cancer: An opportunity for screening and intervention?Molly Morton, Eric M McLaughlin, Corinne A Calo, et al.
Gynecologic Oncology Reports|April 21, 2023
Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?Monica D Levine, David M O'Malley, Paulina J Haight, et al.
Gynecologic Oncology|July 26, 2005
Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group studyBenjamin E Greer, Brian N Bundy, Robert F Ozols, et al.
Gynecologic Oncology|April 3, 2026
Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancerJulia Chalif, Molly Morton, Anna Gonzalez, et al.
Pageof 11

Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
Human Pathology|August 7, 2004
Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative imagesJeffrey D Seidman, Robert A Soslow, Russell Vang, et al.
Gynecologic Oncology|January 30, 2013
Neuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage diseaseGeorgia A McCann, Christina E Boutsicaris, Megan M Preston, et al.
Gynecologic Oncology|August 2, 2014
Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?Floor J Backes, Caroline C Billingsley, Douglas D Martin, et al.
Gynecologic Oncology|February 15, 2011
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancerDavid M O'Malley, Debra L Richardson, Patrick S Rheaume, et al.
Gynecologic Oncology|November 10, 2012
The impact of close surgical margins after radical hysterectomy for early-stage cervical cancerGeorgia A McCann, Susanne K Taege, Christina E Boutsicaris, et al.
Gynecologic Oncology|July 10, 2026
Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter?Paulina J Haight, Julia C Sakach, Laura M Chambers, et al.
Gynecologic Oncology|August 28, 2023
Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship periods following surgical management of endometrial cancer: An opportunity for screening and intervention?Molly Morton, Eric M McLaughlin, Corinne A Calo, et al.
Gynecologic Oncology Reports|April 21, 2023
Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?Monica D Levine, David M O'Malley, Paulina J Haight, et al.
Gynecologic Oncology|July 26, 2005
Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group studyBenjamin E Greer, Brian N Bundy, Robert F Ozols, et al.
Gynecologic Oncology|April 3, 2026
Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancerJulia Chalif, Molly Morton, Anna Gonzalez, et al.
Pageof 11